ProMetic Life Sciences (NASDAQ: CLSD) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Risk and Volatility
ProMetic Life Sciences has a beta of 4.17, meaning that its stock price is 317% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of -7.32, meaning that its stock price is 832% less volatile than the S&P 500.
This table compares ProMetic Life Sciences and Clearside Biomedical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ProMetic Life Sciences||$30.80 million||11.42||-$84.64 million||N/A||N/A|
|Clearside Biomedical||$340,000.00||656.41||-$58.97 million||($2.33)||-2.99|
Clearside Biomedical has lower revenue, but higher earnings than ProMetic Life Sciences.
Institutional & Insider Ownership
0.1% of ProMetic Life Sciences shares are held by institutional investors. Comparatively, 62.9% of Clearside Biomedical shares are held by institutional investors. 15.4% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares ProMetic Life Sciences and Clearside Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ProMetic Life Sciences||-294.06%||-75.00%||-40.35%|
This is a breakdown of current ratings and target prices for ProMetic Life Sciences and Clearside Biomedical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ProMetic Life Sciences||0||0||1||0||3.00|
Clearside Biomedical has a consensus target price of $22.40, indicating a potential upside of 221.38%. Given Clearside Biomedical’s higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than ProMetic Life Sciences.
Clearside Biomedical beats ProMetic Life Sciences on 6 of the 11 factors compared between the two stocks.
About ProMetic Life Sciences
ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies. The Small-Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, chronic kidney diseases/diabetic kidney diseases, and metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes and liver steatosis, and Alström syndrome. The Plasma-Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. The Bioseparation Technologies segment develops and commercializes affinity chromatography products related to the bioseparation, pathogen reduction, and protein purification. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.
About Clearside Biomedical
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.